Proprietary covalent end-point bonding
Covalent end-point bonding allows the heparin to extend into the bloodstream, keeping the active site bioavailable, unlike a non-permanent bond that can be washed away in the bloodstream.
- The anticoagulant function of heparin is dependent on the bioavailability of an active site within the molecule.
- Some methods of covalent heparin bonding damage and / or obstruct the active site, and hence destroy heparin’s anticoagulant activity.
- The CBAS Heparin Surface consists of a proprietary covalent end-point bond that preserves the active site, thus retaining heparin’s anticoagulant activity.